High-Resolution Array CGH in Pregnancy: A Comprehensive Guide

Introduction to Advanced Genetic Testing in Prenatal Care

Modern medicine has revolutionized prenatal diagnostics, offering expectant parents unprecedented clarity regarding fetal health. During pregnancy care, ensuring the healthy development of the fetus is a primary goal. Among the most significant technological breakthroughs in prenatal genetics is High-Resolution Array CGH (Comparative Genomic Hybridization).

This advanced diagnostic tool represents a major leap forward from traditional chromosome analysis. By scanning the fetal genome at an incredibly high resolution, it allows clinicians to detect minute chromosomal imbalances that would otherwise go unnoticed, helping families and healthcare providers make informed management decisions.

What is High-Resolution Array CGH?

Array CGH (Comparative Genomic Hybridization) is a state-of-the-art genetic test used to identify Copy Number Variations (CNVs) in DNA. In simple terms, it scans all 46 chromosomes of the fetus to detect microdeletions (missing genetic material) or microduplications (extra genetic material).

The process involves extracting DNA from a fetal sample and comparing it to a normal reference DNA sample (control). Both DNA samples are labeled with different fluorescent dyes and hybridized onto a glass microarray slide containing thousands of specific genetic probes. By analyzing the fluorescent signals, advanced computer software detects even the smallest gains or losses of genetic material, offering a resolution hundreds of times higher than standard karyotyping.

Why is Array CGH Performed During Pregnancy?

Array CGH is not a routine screening test. Instead, it is recommended by maternal-fetal medicine specialists or clinical geneticists under specific circumstances, including:

• Abnormal Ultrasound Findings: Detection of structural anomalies in the fetal heart, brain, kidneys, or skeletal system, or severe unexplained intrauterine growth restriction (IUGR).
• High-Risk Prenatal Screening Results: Concerning findings from maternal serum screening or non-invasive prenatal testing (NIPT) that suggest a chromosomal abnormality.
• Family History of Genetic Conditions: A previous child or family member with unexplained intellectual disability, developmental delay, or multiple congenital anomalies.
• Recurrent Pregnancy Loss: To investigate whether chromosomal imbalances are contributing to recurrent miscarriages.

Screening vs. Diagnostic Testing

It is crucial for expectant parents to understand the difference between prenatal screening and diagnostic tests. Screening tests (such as maternal blood tests or routine ultrasounds) only estimate the statistical risk of a condition; they do not provide a definitive diagnosis. In contrast, prenatal genetic screening followed by diagnostic Array CGH provides definitive, highly accurate answers.

To perform Array CGH, actual fetal cells must be obtained. This is done through one of two invasive diagnostic procedures:

1. Chorionic Villus Sampling (CVS): Typically performed between weeks 11 and 14 of pregnancy, where a small sample of placental tissue is collected.
2. Amniocentesis: Typically performed after week 15 of pregnancy, where a small amount of amniotic fluid surrounding the fetus is drawn using a fine needle under ultrasound guidance.

Comparison: Traditional Karyotyping vs. Array CGH

The table below highlights the key differences between traditional chromosome analysis (Karyotyping) and High-Resolution Array CGH:

Understanding the Results and the Role of Genetic Counseling

Once the sample is processed, results are typically available within 7 to 14 days. The findings generally fall into three categories:

• Normal Result: No clinically significant copy number variants (gains or losses) were detected. While highly reassuring, it does not rule out single-gene disorders or conditions below the test's resolution.
• Pathogenic Result: A deletion or duplication associated with a known genetic syndrome or developmental disorder was identified, helping the medical team plan appropriate care.
• Variant of Uncertain Significance (VUS): A genetic alteration was found, but its clinical impact is currently unknown. In such cases, testing the biological parents is often recommended to determine if the variant is inherited (usually benign) or occurred spontaneously (de novo).

Given the complexity of these genetic findings, genetic counseling is an indispensable part of the prenatal care pathway in Saudi Arabia. A clinical geneticist or counselor helps families understand the implications of the results, navigate emotional challenges, and discuss available clinical pathways.

Post-Procedure Safety and Red Flags

While CVS and amniocentesis are highly safe when performed by experienced maternal-fetal medicine specialists, they carry a very small risk of miscarriage (less than 0.5%). After undergoing either procedure, patients are advised to rest and avoid strenuous physical activity for 24 to 48 hours.

Expectant mothers must seek immediate medical attention or visit the nearest emergency department if they experience any of the following red flags post-procedure:

• Vaginal bleeding or unusual discharge.
• Continuous leaking of fluid (rupture of membranes).
• Severe abdominal pain or cramping that does not subside with rest.
• Fever, chills, or general malaise.

In conclusion, High-Resolution Array CGH is a powerful diagnostic tool that provides deep genetic insights, helping parents and clinicians navigate pregnancy with greater confidence and clarity. Always consult your healthcare provider to discuss whether this test is appropriate for your clinical situation.